N/A
Completed N=143
HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
Source: ClinicalTrials.gov NCT04389294 ↗Enrolled (actual)
143
Serious AEs
—
Results posted
Jan 2024
Primary outcomePrimary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants
Summary
The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With SARS-CoV-2 IgG Antibodies |
14 | — |
| SECONDARY Differences in Sex Between IgG Antibody-positive vs. Negative Participants |
2; 24; 12; 105 | — |
| SECONDARY Number of Asymptomatic Participants With Positive Antibody Serology |
2 | — |
| SECONDARY Percentage of Antibody-positive Participants Who Subsequently Develop COVID-19 |
12 | — |
| SECONDARY Differences in Race Between IgG Antibody-positive vs. Negative Participants |
10; 99; 2; 6; 2; 18 | — |
| SECONDARY Differences in Average Number of Adults in Household Between IgG Antibody-positive vs. Negative Participants |
14; 129 | — |
| SECONDARY Differences in Comorbidities Between IgG Antibody-positive vs. Negative Participants |
0; 13; 0; 1; 1; 9 | — |
Eligibility Criteria
Inclusion Criteria
- Accredited to practice at HSS
- All anesthesiology and surgery faculty
- All anesthesia and orthopedic surgery fellows
- All orthopedic surgery residents
Exclusion Criteria
- Refusal to participate in either of the interventions at either of the timepoints of interest
Data sourced from ClinicalTrials.gov (NCT04389294). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.